Preoperative Platelet–to–Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection

YOSHIHIRO SHIRAI1,2, HIROAKI SHIBA1, KOICHIRO HARUKI1, TAKASHI HORIUCHI1,2, NOBUHIRO SAITO1,2, YUKI FUJWARA1, TARO SAKAMOTO1, TADASHI UWAGAWA1,3 and KATSUHIKO YANAGA1

1Department of Surgery, 2Division of Gene Therapy, Research Center for Medical Sciences, and 3Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Abstract. Background: The aim of this study was to evaluate a novel prognostic value of preoperative platelet-to-albumin ratio (PAR) in patients resected for pancreatic cancer. Patients and Methods: A total of 107 patients who underwent pancreatic resection for pancreatic cancer were studied. The patients were divided into two groups as PAR ≥46.4×10³ or <46.4×10³. Survival data were analyzed using the log-rank test for univariate analysis and Cox proportional hazards for multivariate analysis. Results: The PAR was a significant prognostic index on univariate analysis for disease-free survival (DFS) and overall survival (OS). The PAR retained its significance on multivariate analysis for OS (hazard ratio(HR)=2.344, 95% confidence interval(CI)=1.188-4.624, p=0.014) along with tumor differentiation and nodal involvement. PAR was a significant independent prognostic index for poor DFS on multivariate analysis (HR=1.971, 95% CI=1.128-3.444, p=0.017). Conclusion: The preoperative PAR is a novel significant independent prognostic index for DFS and OS in patients after pancreatic resection with curative intent.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of cancer and fourth leading cause of cancer related death in developed countries (1), for which pancreatic resection is the only potentially cure treatment, but prognosis after surgical resection remains unsatisfactory. The median survival time after pancreatic resection with curative intent and adjuvant chemotherapy is reported to be only 20-23.6 months (2). Currently, several clinical phase II or III clinical trials including neoadjuvant or adjuvant chemotherapy, immunotherapy or molecular target therapy are ongoing (3). In order to select a relevant therapeutic strategy, preoperative evaluation of cancer prognosis is important.

Recently, it has been recognized that systemic inflammation plays a crucial role in carcinogenesis, tumor progression and metastasis (4). A number of reports demonstrated a correlation between postoperative prognosis and systemic inflammation-based prognostic score, including the Glasgow Prognostic Score (GPS) (5), modified Glasgow Prognostic Score (mGPS) (6), neutrophil-to-lymphocyte ratio (NLR) (7), platelet-to-lymphocyte ratio (PLR) (8), Prognostic Nutrition Index (PNI) (9), and C-reactive protein to albumin ratio (CAR) (10). However, the relation between these prognostic scores and therapeutic outcomes in PDAC are still controversial (11). Preoperative platelet count and serum albumin level are correlated with cancer progression, but to our knowledge there are no reports about any index including both platelet counts and serum albumin level in any type of cancer. Herein we demonstrate the prognostic value of the platelet-to-albumin ratio (PAR), a novel inflammation-based prognostic score, and compared PAR with several existing prognostic scores in patients with PDAC after pancreatic resection with curative intent.

Patients and Methods

Between 2003 and 2013, 121 patients with PDAC underwent pancreatic resection with curative intent at the Department of Surgery, Jikei University Hospital, Tokyo, Japan. We performed a retrospective review of a prospectively maintained database of patients who were histologically diagnosed with PDAC. Patients were excluded as follows: eight were lost to follow-up, one died in hospital, five died from other causes and one committed suicide. A total of 107 patients were therefore studied. This research was approved by the Ethics
Committee of The Jikei University School of Medicine [approval number: 27-177 (8062)]. The detailed pathological factors were based on the seventh edition of the UICC TNM Classification (12). All excised specimens were diagnosed at the Department of Pathology, Jikei University Hospital, Tokyo, Japan. The laboratory data immediately before surgery were evaluated. All borderline cases underwent surgery without neoadjuvant chemotherapy.

We investigated the relation between clinicopathological variables and disease-free (DFS) as well as overall survival (OS) after curative pancreatic resection by univariate and multivariate analyses. The GPS was constructed as previously described (5). NLR (7), PLR (8), PNI (9) and CAR (10) were calculated on the basis of previous studies. PAR was calculated as the platelet count divided by serum albumin level. The cut-off values of these inflammation-based prognostic scores were classified into two groups for the log-rank test and Cox proportional regression model.

Table I lists patient characteristics. Among the study population, the median age was 68 years (25 to 75 percentile of 61-74 years), and 62 of them were male. Eighty-eight percent of patients had stage II or III PDAC. Median OS and DFS after pancreatic resection with curative intent for PDAC were 23.7 and 11.5 months, and 5-year survival rates were 22.6% and 17.1%, respectively.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Value</th>
<th>Range (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>68</td>
<td>61-74</td>
</tr>
<tr>
<td>Gender, male: female</td>
<td>62:45</td>
<td></td>
</tr>
<tr>
<td>Tumor stage: I: II, III</td>
<td>13:94</td>
<td></td>
</tr>
<tr>
<td>Disease-free survival (months)</td>
<td>11.5*</td>
<td>7.7-15.4**</td>
</tr>
<tr>
<td>Overall survival (months)</td>
<td>23.7*</td>
<td>16.0-31.5**</td>
</tr>
<tr>
<td>White blood cell count (x10^3/ml)</td>
<td>5.5</td>
<td>4.5-6.6</td>
</tr>
<tr>
<td>Neutrophil count (x10^3/ml)</td>
<td>3.2</td>
<td>2.5-4.2</td>
</tr>
<tr>
<td>Lymphocyte count (x10^3/ml)</td>
<td>1.5</td>
<td>1.1-1.8</td>
</tr>
<tr>
<td>Platelet count (x10^3/ml)</td>
<td>224</td>
<td>179-260</td>
</tr>
<tr>
<td>Serum albumin (g/dl)</td>
<td>3.9</td>
<td>3.5-4.1</td>
</tr>
<tr>
<td>Serum CRP (mg/l)</td>
<td>1.1</td>
<td>0.5-3.7</td>
</tr>
<tr>
<td>Serum CA19-9 (U/ml)***</td>
<td>99.5</td>
<td>27-341</td>
</tr>
<tr>
<td>PLR</td>
<td>151.3</td>
<td>115.5-190.9</td>
</tr>
<tr>
<td>NLR</td>
<td>2.1</td>
<td>1.6-3.0</td>
</tr>
<tr>
<td>PNI</td>
<td>46.0</td>
<td>42.0-49.5</td>
</tr>
<tr>
<td>CAR</td>
<td>0.03</td>
<td>0.01-0.11</td>
</tr>
<tr>
<td>PAR (x10^3)</td>
<td>57.1</td>
<td>46.1-72.5</td>
</tr>
</tbody>
</table>

IQR: Interquartile range; BMI: body mass index; CRP: C-reactive protein; CA19-9: carbohydrate antigen 19-9; PLR: platelet to lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; GPS: Glasgow Prognostic Score; PNI: prognostic nutritional index; CAR: CRP-to-albumin ratio; PAR: platelet-to-albumin ratio; *median survival time; **95% confidence interval; ***data for 104 patients.

Results

Statistical analysis. Continuous variables are expressed as median and interquartile range. Categorical variables were expressed as absolute numbers. Univariate analyses for categorical data were performed using Chi-square tests. The OS and DFS rates were calculated by Kaplan–Meier method. Comparisons of DFS and OS were performed using the log-rank test for univariate analysis, and the Cox proportional regression model with backward elimination stepwise approach for multivariate analysis. The area under the ROC curve (AUC) were calculated to determine the cut-off value for each prognostic score. p-Values were considered statistically significant when less than 0.05.

Relationship between clinical variables and DFS. The relationship between clinicopathological variables including inflammation-based prognostic scores and OS after pancreatic resection for PDAC are shown in Table II. In univariate analysis, tumor stage (p=0.007), tumor size (p=0.009), nodal involvement (p<0.001), nodal differentiation (p<0.001), preoperative biliary drainage (p=0.002), serum CA19-9 (p=0.001), PLR (p=0.048), CAR (p=0.009), and PAR (p=0.001) were significant prognostic factors of poor patient survival. In multivariate analysis, tumor differentiation (p<0.001), nodal involvement (p=0.001), and PAR (p=0.014) were independent risk factors of poor patient survival. ROC curves were calculated for survival status at 5-year follow-up, and the AUC values were compared to assess cut-offs for each prognostic score as independent risk factors (Table III). The PAR had the highest AUC value (0.690±0.06, p=0.002) compared to the other prognostic scores as independent risk factors (Figure 1).

Relationship between clinical variables and OS. The relationship between clinicopathological variables including inflammation-based prognostic scores and OS after
interleukin (IL) 1, IL6, IL11, IL23 and tumor necrosis factor-α (14). Indeed, IL1 and IL6 are reported to be elevated in patients with thrombocytosis (16). The impact of platelets on cancer is actively recruited to tumor cells through tumor cell-induced platelet aggregation, and adhere to tumor cells by several platelet receptors such as P-selectin, glycoprotein (GP) Ib-IX-V and GPIIb/IIIa (17). The recently described P-selectin, an adhesion molecule expressed on the surface of platelets, binds a variety of tumor cells, and mediates association with other inflammatory cells (18). In addition, P-selectin plays a direct role in tumor growth and metastasis (19). Recruited platelets alter the microenvironment of tumor cells by tumor growth factors, such as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), transforming growth factor-β1 (TGFβ1), and insulin-like growth factor-1 (IGF1). These growth factors are α-granule constituents of platelets and play a crucial role in all stages of cancer progression or promotion, progression and metastasis (13). Cancer cells produce inflammatory cytokines and growth factors such as interleukin (IL) 1, IL6, IL11, IL23 and tumor necrosis factor-α (14). Indeed, IL1 and IL6 are reported to be elevated in patients with PDAC (15), and these cytokines stimulate megakaryocytes to thrombocytosis (16). The impact of platelets on cancer is divided broadly into two categories as cancer progression or protection from immune surveillance system. Platelets are

Table II. Univariate and multivariate analyses of clinicopathological variables in relation to overall survival.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Comparison</th>
<th>N=107</th>
<th>Univariate analysis</th>
<th>HR (95% CI)</th>
<th>p-Value</th>
<th>Multivariate analysis</th>
<th>HR (95% CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor stage</td>
<td>II, III vs. I</td>
<td>94/13</td>
<td>3.193 (1.245-3.977)</td>
<td>0.007</td>
<td>n.s</td>
<td>2.563 (1.739-3.778)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td>≥40 vs. ≤40 mm</td>
<td>39/68</td>
<td>1.881 (1.191-3.186)</td>
<td>0.009</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td>Poor</td>
<td>12</td>
<td>3.495 (2.541-22.19)</td>
<td>&lt;0.001</td>
<td></td>
<td>2.554 (1.599-4.213)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>55</td>
<td>2.544 (1.599-4.213)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Well</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal involvement</td>
<td>Positive vs. negative</td>
<td>71/36</td>
<td>2.434 (1.435-3.589)</td>
<td>&lt;0.001</td>
<td></td>
<td>2.389 (1.337-4.267)</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Resection margin status</td>
<td>Positive vs. negative</td>
<td>31/76</td>
<td>1.419 (0.875-2.455)</td>
<td>0.148</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative biliary drainage</td>
<td>Positive vs. negative</td>
<td>42/65</td>
<td>1.977 (1.343-3.616)</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation</td>
<td>PD: DP: TP</td>
<td>73:31:3</td>
<td>0.438</td>
<td></td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operative time</td>
<td>≥524 vs. &lt;524 min</td>
<td>47/60</td>
<td>1.335 (0.856-2.136)</td>
<td>0.201</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated blood loss</td>
<td>≥455 vs. &lt;455 ml</td>
<td>82/25</td>
<td>1.699 (0.970-2.649)</td>
<td>0.068</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy</td>
<td>Negative vs. positive</td>
<td>17/88</td>
<td>1.133 (0.599-2.174)</td>
<td>0.690</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA19-9*</td>
<td>≥316.5 vs. &lt;316.5 U/ml</td>
<td>28/76</td>
<td>2.207 (1.571-5.165)</td>
<td>0.001</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPS</td>
<td>1, 2 vs. 0</td>
<td>31/76</td>
<td>1.415 (0.869-2.469)</td>
<td>0.154</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NLR</td>
<td>≥1.58 vs. &lt;1.58</td>
<td>79/28</td>
<td>1.414 (0.868-2.276)</td>
<td>0.177</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLR</td>
<td>≥143 vs. &lt;143</td>
<td>45/62</td>
<td>1.575 (1.014-2.493)</td>
<td>0.048</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNI</td>
<td>≥45 vs. &gt;45</td>
<td>45/62</td>
<td>1.238 (0.787-1.986)</td>
<td>0.349</td>
<td>n.s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAR</td>
<td>≥0.032 vs. &gt;0.032</td>
<td>52/55</td>
<td>1.795 (1.170-2.908)</td>
<td>0.009</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAR (×10^3)</td>
<td>≥46.4 vs. &lt;46.4</td>
<td>80/27</td>
<td>2.810 (1.405-6.787)</td>
<td>0.001</td>
<td></td>
<td>2.344 (1.188-4.624)</td>
<td>0.014</td>
<td></td>
</tr>
</tbody>
</table>

Univariate analysis of clinical variables in relation to PAR. The relationship between clinical variables and status of PAR are shown in Table V. The group with a high PAR (≥46.4×10^3) group had larger tumor size (p=0.025), higher frequency of positive nodal involvement (p=0.005), higher frequency of preoperative biliary drainage (p=0.003), higher GPS (p=0.004), higher PLR (p=0.001), and higher CAR (p<0.001).

Relationship between PAR and survival. In univariate analysis, the high PAR (≥46.4×10^3) group had poor median DFS (8.4 vs. 23.3 months, p=0.0032) and OS (18.9 vs. 77.7 months, p=0.0009) compared with the group with low PAR (Figure 2); 5-year OS was 14.7% and 52.1%, respectively.

Discussion

Cancer-related inflammation affects cancer initiation, promotion, progression and metastasis (13). Indeed, IL1 and IL6 are reported to be elevated in patients with PDAC (15), and these cytokines stimulate megakaryocytes to thrombocytosis (16). The impact of platelets on cancer is divided broadly into two categories as cancer progression or protection from immune surveillance system. Platelets are

Table III. Comparison of the area under the receiver operating characteristic curve (AUC) for different prognostic factors.

<table>
<thead>
<tr>
<th>Factor</th>
<th>AUC</th>
<th>95% CI</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor differentiation</td>
<td>0.653±0.06</td>
<td>0.539-0.767</td>
<td>0.012</td>
</tr>
<tr>
<td>Nodal involvement</td>
<td>0.673±0.06</td>
<td>0.558-0.788</td>
<td>0.004</td>
</tr>
<tr>
<td>PAR</td>
<td>0.690±0.06</td>
<td>0.574-0.806</td>
<td>0.002</td>
</tr>
</tbody>
</table>

CI: Confidence interval; PAR: platelet-to-albumin ratio.
cancer progression, including tumorigenesis, angiogenesis, proliferation and metastasis (19). Indeed, the association of these factors and poor survival of patients with PDAC has been clarified (20-22), and these factors are considered valid targets of molecular-targeted therapies (23). Platelets protect tumor cells from the immune system. To transfer to another site, tumor cells have to go through several steps such as detachment of primary cites, intravasation into vascular as circulating tumor cells (CTCs), extravasation into metastasis sites, and proliferation. CTCs are easily attacked by immune...
cells such as natural killer (NK) cells, resulting in their death before metastasis. However, in this step, platelets surround CTCs through tumor cell-induced platelet aggregation, allowing escape from NK cell recognition, and protecting tumor cells from immune attack and physical damage (24). TGFβ and PDGF derived from platelets directly inhibit function of NK cells by down-regulating expression of natural killer group 2 member D (NKG2D) receptor on NK cells (25), which recognizes tumor-specific antigen MHC class I chain-related gene A/B (26, 27). Furthermore, P-selectin not only mediates between platelets and CTCs (28), but also tethers the tumor cell–platelet complex to the microvascular environment in metastatic sites.

The correlation between hypoalbuminemia and poor patient survival has been reported in several types of cancer (29). Hypoalbuminemia is caused by malnutrition and cachexia in patients with cancer, which reduces their response to treatment and increases the risk of anticancer agent-induced toxicity. Systemic inflammation suppresses albumin synthesis in hepatocytes by production of cytokines such as IL6. In addition, metastatic tumor cells induce Kupffer cells in the liver to produce cytokines, and reduce albumin synthesis (29). Consequential hypoalbuminemia is also correlated with impairment of a variety of immune system functions (30), and helps tumor cell promotion and metastasis as a result.

For these reasons, a prognostic index using the platelet count and serum albumin levels seems to be useful for estimation of cancer prognosis in patients with PDAC.

![Graph](Image 326x191 to 525x428)

**Figure 2.** The receiver operating characteristic curve for prediction of 5-year survival by different prognostic factors i.e. tumor differentiation, nodal involvement, and platelet-to-albumin ratio (PAR).

However, as far as we are aware, there has been no report to date on the PAR as an index in any type of cancer. In this study, PAR was a novel significant prognostic factor of poor patient survival in univariate and multivariate analyses.

<table>
<thead>
<tr>
<th>Factor</th>
<th>PAR</th>
<th>p-Value (univariate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor stage (I, II, III)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size, &lt;40 mm: ≥40 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor differentiation, well: moderate: poor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal involvement, negative: positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resection margin status, negative: positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative biliary drainage, negative: positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation, PD: DP: TP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operative time, &lt;524 min: ≥524 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated blood loss, &lt;455 ml: ≥455 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy, negative: positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA19-9, &lt;372: U/ml ≥372 U/ml*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPS, 0: 1, 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NLR, &lt;1.58: ≥1.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLR, &lt;143: ≥143</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNI, &lt;45: ≥45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAR, &gt;0.032: ≤0.032</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table V. Univariate analysis of clinical variables in relation to preoperative platelet to albumin ratio (PAR).

CA19-9: Carbohydrate antigen 19-9; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; CAR: CRP to albumin ratio; *data for 104 patients.
together with tumor differentiation and nodal involvement. Furthermore, PAR had a higher AUC value compared to tumor differentiation and nodal involvement. The measurements of platelet count and serum albumin level are included in routine preoperative evaluation, and all patients who undergo pancreatic resection for PDAC can be examined before surgery. Accordingly, PAR is a very simple tool for estimating the prognosis of patients with PDAC beyond the other inflammation-based prognostic index.

Limitations of this study include its retrospective analysis with potential biases, and the fact that all borderline cases underwent surgery and therefore the influence of neoadjuvant therapy on platelet counts was not considered. By accumulating data prospectively, the benefit of neoadjuvant therapy before surgery for PDAC may be clarified by PAR.

Conflicts of Interest

All Authors have no conflicts of interest to declare in regard to this study.

References


Received December 3, 2016
Revised January 13, 2017
Accepted January 18, 2017